Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176418 · ClinicalTrials.gov registry record · Early Phase 1
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
A Early Phase 1 study of Nicotine Dependence, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05176418: Recruiting Early Phase 1 study of Nicotine Dependence, sponsored by Yale University.
NCT05176418 is a Early Phase 1 study of Nicotine Dependence that is actively recruiting participants, run by Yale University. The registered enrollment target is 70 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05176418, a Early Phase 1 study of Nicotine Dependence, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will examine the impact of the nicotine dose and delivery rate on nicotine's abuse potential, versus its potentially beneficial effects on smoking urges and withdrawal. Will use pulsed IV nicotine administration which closely matches nicotine delivery by inhaled tobacco use.
Primary Outcome
The DEQ measures Good Drug Effect and consists of 11 questions with total score range from 0-100. Higher scores indicate more positive effects.
Conditions Studied
Interventions
- DRUG low dose Nicotine
- DRUG high dose Nicotine
Study Locations (1)
Connecticut
- VA Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-09-09 |
| Est. Completion | 2026-02-01 |
| Phase | Early Phase 1 |
What NCT05176418 shows while recruiting
NCT05176418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 2 interventions - of which low dose Nicotine is the first listed.
NCT05176418 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05176418 about?
NCT05176418 is a clinical study titled "IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate". This project will examine the impact of the nicotine dose and delivery rate on nicotine's abuse potential, versus its potentially beneficial effects on smoking urges and withdrawal. Will use pulsed IV nicotine administration which closely matches nicotine delivery by inhaled tobacco use.
What is the current status of trial NCT05176418?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2022-09-09. Estimated completion is 2026-02-01.
What conditions does trial NCT05176418 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT05176418?
The interventions under investigation include: low dose Nicotine (DRUG), high dose Nicotine (DRUG).
Who is sponsoring clinical trial NCT05176418?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05176418 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05176418's enrollment target sits among peer trials
70 46th of 67 higher than 22 of 67 other Nicotine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nicotine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
COMPLETED · Early Phase 1
-
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
RECRUITING · NA
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
NeuroControl of Nicotine Dependence
RECRUITING · NA
-
Beta-Adrenergic Modulation of Drug Cue Reactivity
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI